Table 2.
Characteristics of ESRD Patients with Shewanella Infection.
| Case | Reference | Country | Age | Sex |
Shewanella species |
Focus | Route of infection |
Antibiotic therapy | Outcome |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 6 | Australia | 62 | M | S. putrefaciens | Oligoarthritis, bacteremia | Respiratory tract | FLUX, GM, PIPC, CPFX | Survival |
| 2 | 7 | Japan | 64 | F | S. algae | Bacteremia | Unknown | CEZ, GM, LVFX, MINO, CFPM | Survival |
| 3 | 8 | Australia | 69 | M | S. putrefaciens | Splenic abscess, bacteremia | Skin ulcer | Unknown | Survival |
| 4 | 9 | USA | 58 | M | S. algae | Myonecrosis, bacteremia | Skin ulcer | CFPM | Survival |
| 5 | 4 | Korea | 67 | M | S. putrefaciens | Necrotizing fasciitis, bacteremia | Skin ulcer | CAZ, MEPM, VCM, DOXY, GM | Death |
| 6 | 10 | USA | 78 | M | S. putrefaciens | Bacteremia | Catheter | GM, MEPM | Survival |
| 7 | 11 | Taiwan | 82 | F | S. putrefaciens | Bacteremia | Catheter | DRPM, AMK | Survival |
| 8 | Present case | Japan | 71 | M | S. algae | Infectious enterocolitis, bacteremia | Oral | MEPM, CAZ, LVFX | Survival |
ESRD: end-stage renal disease, FLUX: flucloxacillin, GM: gentamicin, PIPC: piperacillin, CPFX: ciprofloxacin, CEZ: cefazolin, LVFX: levofloxacin, MINO: minocycline, CFPM: cefepime, CAZ: ceftazidime, MEPM: meropenem, VCM: vancomycin, DOXY: doxycycline, DRPM: doripenem, AMK: amikacin